Hypertension is associated with damage to the heart, kidneys, and vascular tree. Assessment of target organ damage (TOD) allows better prediction of cardiovascular risk than conventional risk assessment. Regression of TOD during antihypertensive treatment, which depends on the blood pressure (BP) reduction and the specific ancillary properties of each drug, may indirectly indicate that BP is well controlled. It is unclear whether regression of TOD during treatment is associated with favorable outcome and should be used as a surrogate endpoint. There is evidence that regression of left ventricular hypertrophy and albuminuria are associated with a favorable outcome. However, recent studies cast doubts on this evidence. Thus, assessment of TOD is important to define cardiovascular risk, but, so far, regression of TOD cannot be regarded as a major surrogate therapeutic target. The present paper will provide a critical overview of the data available in the literature

Shlomai, G., Grassi, G., Grossman, E., Mancia, G. (2013). Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?. THE JOURNAL OF CLINICAL HYPERTENSION, 15(10), 742-747 [10.1111/jch.12185].

Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?

GRASSI, GUIDO;MANCIA, GIUSEPPE
2013

Abstract

Hypertension is associated with damage to the heart, kidneys, and vascular tree. Assessment of target organ damage (TOD) allows better prediction of cardiovascular risk than conventional risk assessment. Regression of TOD during antihypertensive treatment, which depends on the blood pressure (BP) reduction and the specific ancillary properties of each drug, may indirectly indicate that BP is well controlled. It is unclear whether regression of TOD during treatment is associated with favorable outcome and should be used as a surrogate endpoint. There is evidence that regression of left ventricular hypertrophy and albuminuria are associated with a favorable outcome. However, recent studies cast doubts on this evidence. Thus, assessment of TOD is important to define cardiovascular risk, but, so far, regression of TOD cannot be regarded as a major surrogate therapeutic target. The present paper will provide a critical overview of the data available in the literature
Articolo in rivista - Articolo scientifico
hypertension; target organ damage; cardiovascular risk
English
ott-2013
15
10
742
747
none
Shlomai, G., Grassi, G., Grossman, E., Mancia, G. (2013). Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?. THE JOURNAL OF CLINICAL HYPERTENSION, 15(10), 742-747 [10.1111/jch.12185].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/49686
Citazioni
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 27
Social impact